Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
07 janv. 2025 06h00 HE
|
Verona Pharma plc
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions...
Verona Pharma Announces December 2024 Investor Conference Participation
19 nov. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Present at Jefferies London Healthcare Conference
05 nov. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04 nov. 2024 02h00 HE
|
Verona Pharma plc
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled...
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
21 oct. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
30 sept. 2024 02h00 HE
|
Verona Pharma plc
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
05 sept. 2024 02h00 HE
|
Verona Pharma plc
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08 août 2024 02h00 HE
|
Verona Pharma plc
OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST ...
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
30 juil. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
25 juil. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second...